Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls

Key Takeaways Bio-Rad reported Q3 adjusted EPS of $2.26, missing estimates but rising 11.9% year over year.BIO's revenues grew 0.5% to $653 million, surpassing expectations on Life Science and Diagnostics sales.BIO's gross margin contracted 219 bps, while operating profit rose 1.2% and operating margin hit 10%.Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...